MAPT and Alzheimer disease: Asymptomatic at risk refers to preclinical AD in individuals without clinical symptoms, but positive for AD biomarkers (decreased level of Aβ42, increased the level of tau p-tau in CSF) or positive in Aβ-PET (Dubois et al., 2014).